CT Prediction for Transcatheter Tricuspid Interventions

Last updated: April 22, 2025
Sponsor: Heart and Diabetes Center North-Rhine Westfalia
Overall Status: Active - Recruiting

Phase

N/A

Condition

Congestive Heart Failure

Treatment

N/A

Clinical Study ID

NCT06951126
HDZ-KA CESAR-TR
  • Ages > 18
  • All Genders

Study Summary

The aim of this study is to enhance the predictability of therapeutic success in transcatheter tricuspid valve intervention (TTVI) for patients with severe tricuspid regurgitation (TR). This will be achieved through automated analyses of pre-interventional computed tomography (CT) scans.

Severe tricuspid regurgitation is associated with poor patient outcomes. In advanced stages, pharmacological therapy becomes ineffective, and surgical intervention carries a high mortality risk. Given this clinical challenge, catheter-based treatment of the tricuspid valve has become a focal point of research.

One well-established treatment strategy is percutaneous tricuspid valve intervention, which aims to reduce regurgitation either through annuloplasty, leaflet-based edge-to-edge repair or valve replacement. This approach has been shown to significantly decrease the severity of regurgitation, leading to a dramatic reduction in symptom burden and a marked improvement in quality of life.

However, predicting which patients will benefit most from TTVI and determining the optimal technique for each individual remain largely unresolved challenges.

Artificial intelligence (AI)-powered software, such as heart.ai by LARALAB (Munich), enables automated measurement of anatomical structures captured via CT imaging. This technology already allows for rapid and precise assessment of cardiac chambers and the tricuspid annulus throughout the entire cardiac cycle, facilitating a comprehensive three-dimensional evaluation of right heart anatomy.

To refine patient selection and optimize procedural strategies for TR treatment, the researcher work a multi-center collaboration to analyze treatment outcomes and patient response to specific therapeutic approaches.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • the patient underwent full cycle cardiac computed tomography for analysis ofvalvular heart disease

  • a transcatheter tricuspid valve intervention is performed

  • the patient is 18 years or older

Exclusion

Exclusion Criteria:

  • none

Study Design

Total Participants: 500
Study Start date:
July 19, 2023
Estimated Completion Date:
June 01, 2030

Connect with a study center

  • Herz- und Diabeteszentrum

    Bad Oeynhausen, NRW 32545
    Germany

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.